Trial reportSurgery today2018
Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan.
Trial report in Surgery today, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 6 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Pharmacological Strategies for Preventing Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Interventions for maintenance of surgically induced remission in Crohn's disease: a systematic review and network meta-analysis.BMJ open gastroenterology · 2025Pooled it
- A Systematic Review on Long-Term Efficacy Outcome Measures in Crohn's Disease Patients.Journal of Crohn's & colitis · 2023Pooled it
- Disease recurrence in patients with Crohn's disease after biologic therapy or surgery: a meta-analysis.International journal of colorectal disease · 2022Pooled it
- Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis.The Cochrane database of systematic reviews · 2019Pooled it
- A Meta-Analysis of Efficacy and Safety of Infliximab for Prevention of Postoperative Recurrence in Patients with Crohn's Disease.BioMed research international · 2018Pooled it
- Efficacy of Advanced Therapies as Prophylaxis and for Active Disease in Postoperative Crohn's Disease: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Management of Post-Operative Crohn's Disease: Knowns and Unknowns.Journal of clinical medicine · 2024Review
- Review
- Antimesenteric cutback end-to-end isoperistaltic anastomosis (Sasaki-Watanabe anastomosis) for Crohn's disease: Novel surgical technique and early results of surgical anastomotic recurrence.Annals of gastroenterological surgery · 2021Article
- A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively.Case reports in oncological medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe prevention of postoperative recurrence is a critical issue in surgery for Crohn's disease. Prospective randomized trials in Western countries have shown that the postoperative use of anti-tumor necrosis factor α-antibodies was effective in reducing the recurrence rate. We investigated the efficacy of infliximab (IFX) for the prevention of postoperative Crohn's disease recurrence.
methodsWe performed a prospective randomized multicenter study. Patients who underwent intestinal resection were assigned to groups treated with or without IFX. Immediately after surgery, patients in the IFX group received IFX at 5 mg/kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years. The primary study outcome was the proportion of patients with endoscopic and/or clinical recurrence at 2 years after surgery.
resultsThirty-eight eligible patients participated in this study: 19 in the IFX group and 19 in the non-IFX group. The disease recurrence rate in the IFX group was 52.6% (10/19), which was significantly lower than that in the non-IFX group (94.7% [18/19]).
conclusionThe postoperative use of IFX is effective in preventing Crohn's disease recurrence for 2 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.